Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It is involved in developing neurology products that include IONIS-HTTRx for Huntington's diseases; and IONIS-SOD1Rx and IONIS-C9Rx for amyotrophic lateral sclerosis and IONIS-MAPTRx for Alzheimer's diseases.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone760-931-9200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$599.67 million
Profitability
Miscellaneous
Employees737
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions
What is Ionis Pharmaceuticals' stock symbol?
Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."
How were Ionis Pharmaceuticals' earnings last quarter?
Ionis Pharmaceuticals Inc (NASDAQ:IONS) released its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.01) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.27) by $0.26. The business had revenue of $164 million for the quarter, compared to analysts' expectations of $145.31 million. Ionis Pharmaceuticals had a return on equity of 38.70% and a net margin of 49.90%. The company's revenue was up 39.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.29) earnings per share. View Ionis Pharmaceuticals' Earnings History.
When is Ionis Pharmaceuticals' next earnings date?
What price target have analysts set for IONS?
11 equities research analysts have issued 12-month target prices for Ionis Pharmaceuticals' stock. Their predictions range from $50.00 to $120.00. On average, they expect Ionis Pharmaceuticals' share price to reach $76.60 in the next year. This suggests a possible upside of 35.9% from the stock's current price. View Analyst Price Targets for Ionis Pharmaceuticals.
What is the consensus analysts' recommendation for Ionis Pharmaceuticals?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ionis Pharmaceuticals.
What are Wall Street analysts saying about Ionis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Ionis Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California. " (10/16/2019)
- 2. Cantor Fitzgerald analysts commented, ". $68 PT. Biogen (BIIB, Young, Neutral) reported earnings this morning and discussed the outlook for Spinraza, which is a key product for Ionis (receives low-20s royalty). Incremental color suggests that the broader SMA market, especially ex-US, is likely much larger than initially expected. However, we see disruptive potential from competitors (risdiplam and gene therapy) which continues to leave us cautious on the long-term Spinraza opportunity. We are hosting a conference call on Monday at 10 AM ET to discuss our thoughts on the key SMA competitor updates expected at AAN (early May) and stock reads to IONS, BIIB and PTCT (Overweight, Young). Call details below." (4/24/2019)
Has Ionis Pharmaceuticals been receiving favorable news coverage?
News articles about IONS stock have been trending somewhat negative on Thursday, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ionis Pharmaceuticals earned a media sentiment score of -1.9 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Ionis Pharmaceuticals.
Are investors shorting Ionis Pharmaceuticals?
Ionis Pharmaceuticals saw a drop in short interest during the month of September. As of September 30th, there was short interest totalling 10,510,000 shares, a drop of 6.7% from the August 30th total of 11,260,000 shares. Based on an average trading volume of 1,040,000 shares, the short-interest ratio is presently 10.1 days. Approximately 8.2% of the shares of the company are sold short. View Ionis Pharmaceuticals' Current Options Chain.
Who are some of Ionis Pharmaceuticals' key competitors?
Some companies that are related to Ionis Pharmaceuticals include Regeneron Pharmaceuticals (REGN), Shiseido (SSDOY), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), UCB (UCBJF), Genmab A/S (GNMSF), BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Elanco Animal Health (ELAN), Mylan (MYL), Ono Pharmaceutical (OPHLF) and Alnylam Pharmaceuticals (ALNY).
What other stocks do shareholders of Ionis Pharmaceuticals own?
Who are Ionis Pharmaceuticals' key executives?
Ionis Pharmaceuticals' management team includes the folowing people:
- Dr. Stanley T. Crooke, Founder, Chairman, CEO & Pres (Age 74)
- Dr. Brett P. Monia, Founder, COO, Sr. VP of Translational Medicine & Director (Age 58)
- Ms. Elizabeth L. Hougen, Sr. VP of Fin. & CFO (Age 57)
- Dr. Richard S. Geary, Sr. VP of Devel. (Age 61)
- Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 65)
Who are Ionis Pharmaceuticals' major shareholders?
Ionis Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (0.14%), Decatur Capital Management Inc. (0.05%), Envestnet Asset Management Inc. (0.04%), Gateway Investment Advisers LLC (0.03%), DNB Asset Management AS (0.01%) and Robeco Institutional Asset Management B.V. (0.01%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce, Spencer R Berthelsen and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.
Which institutional investors are selling Ionis Pharmaceuticals stock?
IONS stock was sold by a variety of institutional investors in the last quarter, including Decatur Capital Management Inc., Nisa Investment Advisors LLC and Envestnet Asset Management Inc.. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.
Which institutional investors are buying Ionis Pharmaceuticals stock?
IONS stock was bought by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Robeco Institutional Asset Management B.V., Sumitomo Mitsui DS Asset Management Company Ltd, Gateway Investment Advisers LLC and DNB Asset Management AS. View Insider Buying and Selling for Ionis Pharmaceuticals.
How do I buy shares of Ionis Pharmaceuticals?
Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Ionis Pharmaceuticals' stock price today?
One share of IONS stock can currently be purchased for approximately $56.37.
How big of a company is Ionis Pharmaceuticals?
Ionis Pharmaceuticals has a market capitalization of $7.92 billion and generates $599.67 million in revenue each year. The company earns $273.74 million in net income (profit) each year or $2.96 on an earnings per share basis. Ionis Pharmaceuticals employs 737 workers across the globe.View Additional Information About Ionis Pharmaceuticals.
What is Ionis Pharmaceuticals' official website?
How can I contact Ionis Pharmaceuticals?
Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200.
MarketBeat Community Rating for Ionis Pharmaceuticals (NASDAQ IONS)
MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe IONS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IONS will underperform the S&P 500 over the long term. You may vote once every thirty days.
